Valbiotis Logo

Valbiotis

ALVAL | PA

Overview

Corporate Details

ISIN(s):
FR0013254851
LEI:
969500VP4JBJCF0MOP60
Country:
France
Address:
RUE PAUL VATINE, 17180 PERIGNY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Valbiotis is a research and development company committed to scientific innovation for the prevention and management of metabolic and cardiovascular diseases. The company specializes in developing and marketing plant-based, clinically tested dietary supplements and active substances. Its core focus is on major health risk factors including prediabetes, dyslipidemia, arterial hypertension, and metabolic liver diseases. Leveraging its botanical expertise, Valbiotis creates multi-target active substances that act on multiple physiological pathways. The company's product portfolio, including the ValbiotisPRO® range, is distributed through pharmacies and is aimed at both healthcare professionals and consumers seeking scientifically validated natural health solutions.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Valbiotis. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-11 17:30
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 18.2 KB
2025-07-03 17:45
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 165.4 KB
2025-07-03 17:45
Regulatory News Service
VALBIOTIS SA: Bilan semestriel du contrat de liquidité
French 359.3 KB
2025-07-03 17:45
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 19.3 KB
2025-06-26 17:40
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the success of its €6.9 million rights issue …
English 470.3 KB
2025-06-26 17:40
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis annonce le succès de son augmentation de capital de 6,9…
French 419.2 KB
2025-06-26 17:40
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the success of its 6.9 million rights issue e…
English 142.5 KB
2025-06-06 08:00
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintai…
English 579.9 KB
2025-06-06 08:00
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis annonce le lancement d’une augmentation de capital avec…
French 511.1 KB
2025-06-06 08:00
Share Issue/Capital Change
VALBIOTIS SA: Valbiotis announces the launch of a capital increase with maintai…
English 305.6 KB
2025-06-02 22:48
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 131.2 KB
2025-06-02 22:48
Declaration of Voting Results & Voting Rights Announcements
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
French 18.1 KB
2025-05-22 17:40
Earnings Release
VALBIOTIS SA: Valbiotis to launch ValbiotisPRO® Cardio-circulation on 2 June
English 235.0 KB
2025-05-22 17:40
Regulatory News Service
VALBIOTIS SA: Valbiotis commercialisera le 2 juin prochain  sa solution Valbio…
French 201.0 KB
2025-05-22 17:40
Regulatory News Service
VALBIOTIS SA: Valbiotis to launch ValbiotisPRO Cardio-circulation on 2 June
English 27.2 KB

Automate Your Workflow. Get a real-time feed of all Valbiotis filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Valbiotis via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-01-17 N/A Other Other 10,400 46,072.00 EUR

Peer Companies

Company Country Ticker View
Orion Oyj Logo
Develops and markets human/vet pharmaceuticals and APIs, focusing on oncology and pain management.
Finland ORNAV
Otsuka Holdings Co., Ltd. Logo Japan 4578
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom OXB
PAION AG Logo
Developed innovative drugs for hospital sedation, anesthesia, and critical care.
Germany PA8
PeptiDream Inc. Logo Japan 4587
PEPTONIC Medical AB Logo
Develops clinically proven self-care products and diagnostics for women's intimate health.
Sweden PMED
Perseus Proteomics Inc. Logo Japan 4882
Pharma Mar S.A. Logo
Develops and commercializes marine-derived oncology treatments for rare cancers.
Spain PHM
Pharmanutra Logo
Develops science-backed nutraceuticals & pharmaceuticals for nutritional & joint health.
Italy PHN
PharmaSGP Holding SE Logo
Develops & distributes natural, pharmacy-exclusive OTC drugs for chronic conditions in Europe.
Germany PSG